Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed and Refractory Multiple Myeloma (RRMM)”

140 trials

Showing 20 of 140 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT05909826
What this trial is testing

Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM

Who this might be right for
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
Dong-A University Hospital 49
Not applicableUnknownNCT05297240
What this trial is testing

Retrospective Study of the Use of Belantamab Mafodotin (Blenrep®) in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) in Spain.

Who this might be right for
RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA
PETHEMA Foundation 170
Testing effectiveness (Phase 2)Looking for participantsNCT07266441
What this trial is testing

JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 157
Large-scale testing (Phase 3)Looking for participantsNCT05730036
What this trial is testing

A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed Refractory Multiple Myeloma (RRMM)
Regeneron Pharmaceuticals 410
Testing effectiveness (Phase 2)Active Not RecruitingNCT04126200
What this trial is testing

Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Who this might be right for
Multiple Myeloma
GlaxoSmithKline 208
Testing effectiveness (Phase 2)Looking for participantsNCT06484829
What this trial is testing

Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma (RRMM)
Chengdu Zenitar Biomedical Technology Co., Ltd 144
Testing effectiveness (Phase 2)Ended earlyNCT02807454
What this trial is testing

Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Celgene 37
Not applicableActive Not RecruitingNCT06479954
What this trial is testing

Non Interventional Study to Investigate the Safety and Effectiveness in Patients With Relapsed and Refractory Multiple Myeloma Treated With Elranatamab Under the Actual Use.

Who this might be right for
Relapsed and Refractory Multiple Myeloma (RRMM)
Pfizer 1
Not applicableStudy completedNCT02555839
What this trial is testing

Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice

Who this might be right for
Multiple Myeloma
Celgene 127
Large-scale testing (Phase 3)Active Not RecruitingNCT05552976
What this trial is testing

Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Bristol-Myers Squibb 525
Testing effectiveness (Phase 2)WithdrawnNCT03221634
What this trial is testing

Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)

Who this might be right for
Multiple Myeloma
Merck Sharp & Dohme LLC
Not applicableActive Not RecruitingNCT04458831
What this trial is testing

A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Plasma Cell Myeloma
Sanofi 583
Testing effectiveness (Phase 2)Study completedNCT02046070
What this trial is testing

Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Millennium Pharmaceuticals, Inc. 148
Testing effectiveness (Phase 2)WithdrawnNCT05647512
What this trial is testing

Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases

Who this might be right for
Relapsed or Refractory Multiple MyelomaOther Plasma Cell Diseases
LaNova Medicines Limited
Large-scale testing (Phase 3)Active Not RecruitingNCT03651128
What this trial is testing

Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

Who this might be right for
Multiple Myeloma
Celgene 381
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07348393
What this trial is testing

A Phase 2, Single Arm Multicenter, Study Testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Relapsed or Refractory Multiple Myeloma (RRMM)
Assistance Publique - Hôpitaux de Paris 70
Testing effectiveness (Phase 2)Active Not RecruitingNCT07150104
What this trial is testing

Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM

Who this might be right for
Multiple Myeloma
GlaxoSmithKline 14
Testing effectiveness (Phase 2)Looking for participantsNCT06106945
What this trial is testing

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
AstraZeneca 226
Early research (Phase 1)Not Yet RecruitingNCT07082270
What this trial is testing

Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma

Who this might be right for
Recurrent Multiple MyelomaRefractory Multiple Myeloma
Roswell Park Cancer Institute 21
Large-scale testing (Phase 3)Active Not RecruitingNCT04162210
What this trial is testing

Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Who this might be right for
Multiple Myeloma
GlaxoSmithKline 325
Load More Results

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation